

Financial Results Report

2Q FY 06/2025

OLBA HEALTHCARE HOLDINGS, INC.
(formerly KAWANISHI HOLDINGS INC.)

This presentation includes machine translation.
Please consider that some content may not be perfectly accurate or contextually appropriate.

(Securities code: 2689)



つなぐ、人と未来。

OLBA
HEALTHCARE

Contents

- ◆ **Corporate Philosophy**
- ◆ **Summary of FY2025 and 2Q**
- ◆ **FY2025 FY June 2025 Performance Forecasts and Basic Policy for Distribution**
- ◆ **Outline of the Medium-Term Management Plan**
- ◆ **Reference Materials**

Corporate Philosophy



OLBA
HEALTHCARE

Corporate Philosophy and Significance of Presence (purpose)

Through our business, Contributing to the development of medicine, medical care, and nursing care, Contribute to the health and longevity of the national



社員憲章

事業のあり方

- ビジネスを通じて、医学・医療・介護の発展に貢献し、国民の健康長寿に寄与する
- 革新的な新機能・新技術の恩恵を、患者と医療機関に速やかに適切に提供する
- ステークホルダー（顧客、取引先、社員、地域社会、株主）の皆様に、誠実かつ継続的に価値を提供し、持続可能な経営を追求する
- 業界の内外を問わず積極的に交わり、創造性を育み、グローバルな視点でフロンティアを探索する

組織のあり方

- 人材育成を専び、「マネジメント（人を通じて事を成す）」に重きをおく



FY June 2025
Overview of Results for 2nd quarter FY6/25



OLBA
HEALTHCARE

■ Global inflation and depreciation of the yen

- Prices of medical devices, many of which are overseas products, continue to trend upward
- Implemented measures to expand sales activities and improve purchasing
- Negotiations to pass on the increase to sales prices are conducted while considering proposals for alternative products.
Secure a certain level of profit

■ Establishment of Kansai Branch in mainstay medical equipment business

- Acquired customers in the Kansai area and promoted Kobe Sales Office to Kansai Branch

■ Strong sales of consumables

- Establishment of a cooperative system with Olympus Marketing
⇒ Even after the start of operations in April 2023, total sales of digestive endoscopy-related products rose 9.1% YoY
- Acquisition of new facilities in Kansai area
⇒ Total sales of cardiovascular consumables increased 8.7% year on year

Consolidated Financial Results for the Second Quarter of Fiscal 2025

[2Q]

Record high net sales, gross profit, and interim net income attributable to owners of the parent

	Millions of yen	Comparison with budget	YoY
Net sales	60,627	Δ0.2%	+5.5%
Gross profit	6,819	Δ1.5%	+6.0%
Gross profit margin	11.25%		
SG&A expenses	6,011	Δ1.8%	+5.8%
Operating income	808	+1.0%	+8.2%
Ordinary income	824	+3.9%	+10.5%
Profit attributable to owners of parent	648	+27.2%	+33.3%


[Regarding the difference in interim net income attributable to owners of the parent]
 Along with the plan to integrate the headquarters of subsidiaries,
 Impact of tax effect accounting for impairment losses on real estate in prior years

Interim net income per share 109.44 yen

Business Segment Results for the Second Quarter of Fiscal 2025

Sales Mix

■ Medical equipment ■ SPD ■ Nursing care products



[FY June 2025 2Q] Net Sales (Operating Income) ※ Sales include inter-segment sales

57.2 billion yen
(710 million yen)




Medical equipment business
Total partners in the medical field

2.8 billion yen
(50 million yen)



SPD business
Medical products distribution specialist

1.3 billion yen
(100 million yen)



Nursing Care Products Business
Total support for nursing care products

Medical equipment business




Total partners in the medical field

Millions of yen	Actual	Comparison with budget	YoY change
Net sales ※1	57,294	+0.1%	+5.5%
Operating income	715	Δ0.1%	+6.9%



Medical equipment [93.2%]



Millions of yen	Sales Results ※2	YoY
Kawanishi Corporation	38,625	+6.2%
Sansei Medical	13,290	+0.7%
Nikko Medical Instruments	5,969	+12.0%

※1 Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

※2 Sales results of individual companies include the amount of transactions between group companies

Medical Equipment Business Consumables

Sales ¥52 billion up 7.6% year on year

Millions of yen

Product Classification	Net sales	YoY	Points of sub-segments
Surgical consumables	25,970	+5.7%	Internal medicine +15.6%, digestive endoscopes +9.1%, surgical +6.6%
Orthopedic consumables	14,126	+10.3%	Artificial joint +12.1%, trauma, sports, and arthroscopes +9.7% Spine Δ 10.9%
Cardiovascular consumables	11,938	+8.7%	Catheterization ABL*+14.6%, cardiac ischemic treatment + 13.3%. Cardiac and Vascular Surgery Δ 0.7%

* ABL: Therapy in which a portion of the heart is catheterized for a tachyarrhythmia, such as auricular fibrillation, to be ablated or frozen



Ultrasound scalpel

Johnson & Johnson K.K.
From our website (<https://www.jnj.co.jp/>)



Artificial knee joint

Zimmer Biomet website
Than <https://www.zimmerbiomet.com/ja>



Pacemaker

Medtronic website
From (<http://www.medtronic.com/>)

※Net sales (including changes from the previous fiscal year) are calculated based on management accounting before the adoption of the new revenue recognition standard.

Medical Equipment Business Equipment

Sales ¥6.5 billion down 5.8% year on year

Points of Equipment Sales

- ◆ Increase in demand due to subsidies such as corona paused
- ◆ Small number of large-scale projects, strengthen discovery of small-scale equipment projects
- ◆ Sales of automated payment machines for clinics were strong.



Automatic reset machine

From kawanishibarkmed HP
(<https://kawanishi-bm.co.jp/>)



Pulmotor

Philips website
Than <https://www.philips.co.jp/healthcare>



**With analysis function
Vital signs monitor**

Fukuda Electronic Website
From (<https://www.fukuda.co.jp/>)

Medical products distribution specialist

Millions of yen	Actual	Comparison with budget	YoY
Net sales ※	2,842	+1.7%	+9.8%
Operating income	55	+2.6%	+5.3%

※Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

Total number of subscribers
74 direct
FC 2

- ◆ Review of commodity management service fees
- ◆ Passing on increases in purchase prices to higher prices and making improvements in purchases
- ◆ Increase in SG&A expenses due to the impact of salary base pay increases, etc.



Goods management



Information management



Purchasing management



Total support for nursing care products

Millions of yen	Actual	Comparison with budget	YoY
Net sales ※	1,369	+0.1%	+4.0%
Operating income	105	△3.3%	+3.4%

※Net sales (including changes from budget and changes from the previous fiscal year) include intersegment sales

- ◆ Continued demand for home medical care and in-home nursing care
- ◆ Mainstay nursing care product rentals up 4.4% YoY
- ◆ Sales of merchandise and housing renovations associated with rentals are also steady



Rental



Sale



Renovation



**From the FY2025 results forecast
Basic policy on dividends**



OLBA
HEALTHCARE


Consolidated Financial Forecasts for the Fiscal Year Ending June 2025

Sales, gross profit, operating profit, and recurring profit are expected to be record highs

(Millions of yen)	Forecast	2024/6 Result	Change
Net sales	123,726	118,564	+4.4%
Gross profit	14,446	13,600	+6.2%
Gross profit margin	11.68%	11.47%	+0.21
SG&A expenses	12,176	11,374	+7.1%
Operating income	2,270	2,226	+1.9%
Ordinary income	2,253	2,244	+0.4%
Profit attributable to owners of parent	1,465	1,500	△2.4%

Net income per share ¥247.65

Factors behind Changes in Operating Income for the Fiscal Year Ended June 2025




[Consolidated net sales] Record forecast

**FY June 2025 Forecast of ¥123.7 billion
(+4.4% YoY)**

Fifth consecutive year of sales growth and record highs

(Millions of yen) 160,000




[Consolidated Operating Profit] Record forecast

Forecast for FY6/2025: ¥2.27 billion
(Up 1.9% year on year)

Fifth consecutive year of profit growth and record highs


(Millions of yen) 2,500



Basic policy on dividends

- ① Aiming to increase or maintain dividends
- ② We will endeavor to retain internal reserves for growth investments.

FY6/25 forecast: JPY80



※Dividend yield is calculated based on the share price at the end of each fiscal year.

Financial indicators we emphasize

✓ Net sales

✓ Operating income

✓ **ROE** (Return on Equity) = $\frac{\text{Net income}}{\text{Shareholders' equity}} \times 100\%$ Profitability improvement

Aiming to improve PBR by improving profitability, promoting new businesses, etc.

PBR = PER x ROE = $\frac{\text{Market capitalization}}{\text{Net income}} \times \frac{\text{Net income}}{\text{Shareholders' equity}}$


Dialogue with the market

- Upstream strategy
- New businesses
- Overseas expansion

Fostering expectations for growth

Profitability improvement


Analysis of Capital Cost and Capital Profitability



- Equity spread (%)
(Cost of ROE-equity)
⇒ Approx. 6% to 7%
- For the cost of capital on an ongoing basis
Achieve higher profitability on capital
- Five-year historical mean of ROE
⇒ 12.7%
- **In line with its medium-term management plan**
Continue to invest for growth and development

※ Reference value for calculating cost of equity
 • Risk-free rate: 10-year JGB yields, β value: about 0.8, market risk premium: about 7%

Initiatives to Improve PBR



Outline of the Medium-Term Management Plan




OLBA
HEALTHCARE

Domestic market size of medical devices

Stable market growth despite policies to curb medical costs

- Recovering from the Impact of the New Corona and Stable Market Expansion
- Market expansion due to increase in number of surgeries and introduction of new products

In fiscal 2024,
Forecast of ¥3.794 trillion




* Processed from the 2023 edition of the Medical Equipment and Supply Yearbook and the 2024 edition of the Medical Equipment and Supply Yearbook of R&D Co., Ltd.

Medium-term management plan

(FY June 2027: ¥135 billion in sales, ¥2.7 billion in operating profit)

Key Points of the FY2025/6-2027/6 Medium-Term Management Plan



Medium-Term Management Plan: Key Points of Initiatives

- **OLBA-DX** : Utilization sales quality by streamlining operations and utilizing ICT tools
Working to improve employee IT skills
- **Improve productivity**: Strengthen current operations and innovate logistics (construct new logistics center)
Aiming to realize stable supply and maximize value provided to customers
- **Invest in the future** : Realize development of new businesses and sustainability
Promoting human capital investment and initiatives that take the global environment into account



On subsequent slides

『OLBA-DX』

"Logistics innovation"

"New Business Development"

Explanation focused on "Sustainability"

Measures already in operation and in progress

- **Creating new value**
 - Developing and operating Web order apps
- **Sales support and operational efficiency**
 - Sales Assistance through Unique Electronic Catalog
 - Business card management system in operation
 - Expense settlement system in operation
 - Development and operation of integrated logistics system in progress
 - Expanded use of RPA and no-code tools
- **Strong security measures**
 - EDR (Endpoint Security) in Operation
 - Initiatives for information security



Initiatives to be implemented in the future

- **Promote further sales support and operational efficiency**
 - CRM, SFA construction
 - Renovation of the sales management system
 - Renovation of groupware
 - Expand use of generated AI

Study Group on Utilization of No-Code Tools

A study session was held in Okayama City in November 2024.

Group work and other activities conducted by employees selected from Group companies

Study sessions on utilization of generated AI, etc.
To be implemented as appropriate in the future



Other company-wide initiatives

Conducted DX literacy training for all employees by e-Learning and assessed comprehensiveness

We also encourage employees to take IT passport exams.

● Operation of Li-Flo, an integrated logistics system

Started operation in September 2022 sequentially from the Kawanishi base of the operating companies

⇒ Expand of the introduction to the entire group



Reinforcement in
inventory control

To reinforce quality
management

Streamlining of lending
business

Effects at Introduction Sites

- Improving the efficiency of product pick and delivery slip output and reducing inventory time through barcode reading and system linkage, etc.

● Shin-Okayama Distribution Center Construction

Decided to construct a new logistics center for the medical equipment business,
scheduled to begin operations in July 2027

Purpose of construction

- Streamlining operations, BCP measures, and building new logistics networks
- Hub base for the supply of medical equipment in the Chugoku-Shikoku region


⇒ Based on the philosophy of "do not stop medical care," we will be responsible for the stable supply of medical devices as a base that supports regional medical care.



New Businesses ① Strong sales of Temasac

Temasac series of automated settlement machines for clinics

- Introduction in the July-December quarter of 2024 : 165 units (YoY +65 units)
- Cumulative number of vehicles introduced : 664 units (As of the end of December 2024)



Following Tokyo, Nagoya, Osaka, Okayama, and Fukuoka, Opened sales base in Hokkaido in July 2024

(January 6, 2025)

New Businesses ② Established Orcido Co., Ltd.



To foster new businesses

Minimize environmental impact

Started sales of OLSTECH, a low-thermal decomposition-type up-cycle unit

Olstech Corp.



低熱分解型アップサイクルユニット

「OLSTECH」

大阪大学 環境安全研究管理センターとの共同研究開発

特許取得済



廃プラや食品残渣、生ゴミ、木くず、排泄物などさまざまな有機性の廃棄物に対応しています。有機物であれば分別する必要はなく、運用方法はユニットにまとめて投入するだけです。

炉内では化学反応熱を利用して持続的に低熱分解が行われ、投入してから数時間程度で、有機物が細かく炭化・減容され、最終的に炭酸カルシウムを主成分とする炭酸塩へと変換されます。

電源があれば、24時間365日稼働可能で管理者の立ち会いも不要です。

OLSTECH| Three characteristics

- 1) Significant reductions in CO2 and dioxin emissions
- 2) Organic garbage reduced in size to 1/300 volume, secondary use
- 3) Space saving & low running cost (fossil fuel not used)

- The development concept produces no garbage
- In November 2024 on a remote island in Taketomi-cho, Okinawa Started operation trials to resolve waste issues

New businesses ③ "Babyeets®" launched

Babies

To foster new businesses

Newborn Live Distribution & Memorial Movie Creation Service "Babyeets®"

Babies



Babyeets | Three characteristics

- 01 Easy access to read-only cards
- 02 Real-time video viewing from remote areas
- 03 Provision of memorial video after hospitalization

[Thoughts on development]

- With inspiration and newborn records immediately after delivery
Deliver to families and relatives
- To the promotion of attachment to newborns
Aim to contribute



Left: Memorial movie sample
Right: Interview with Director Sugiyama,
Ehime University

Started operation at Ehime University Hospital in December 2024

Reasons for expanding into Thailand

- Economic and geographic hub-function of ASEAN region
- Expect rapid aging in the future
- Thailand government focuses on fostering the medical industry

Main businesses of Tyolba Healthcare

➤ Sales of fully automated tablet packaging machines

Concluded an official sales agent agreement with

Takazono Co., Ltd. in Thailand

Preparing for installation at hospitals

➤ Sales of rehabilitation equipment

In cooperation with Morito Co., Ltd. and other Japanese manufacturers, preparations for sales are underway

[Commemorative ceremony for the establishment of Bangkok on January 26, 2023]



[Authorized sales agent in Thailand for Takazono Products Co., Ltd]

TAKAZONO

Fully automated tablet packaging machine

Automatic dispensing table

©OLBA HEALTHCARE HOLDINGS, Inc.

Takazono <https://www.takazono.co.jp/index.html> Co., Ltd.
Morito <https://www.moritoh.co.jp/> Co., Ltd.

Environment (environmental)

Started sales of OLSTECH, a low-thermal decomposition-type up-cycle unit

Social (Social)


[Human capital investment and work style reform]

Increase of male employees taking childcare leave by 4-5% on regular pay raise + bears
Efforts to promote women's careers and improve employee engagement are underway



[Health Management]

Health and Productivity Management Strategy Map under development
Sep. 2024 Introduced long-term revenue support system (GLTD system)



[For local communities]

Provision of safe and high-quality medical and nursing care equipment and services

Governance (Governance)

Ensure management transparency, efficiency, and soundness. Enhancement of Group Value

Our strengths and utilization and weaknesses and countermeasures

Strengths and Utilization

- **No.1 of shares in Chugoku-Shikoku region (based on trust from customers and suppliers)**
⇒ New investments can be implemented by securing stable profits
- **To invest in human resource development and DX, which are the source of our growth**
⇒ Accurately grasping customer needs through approximately one year of new employee training, etc.
⇒ Supporting sales activities through the utilization of ICT tools

Weaknesses and countermeasures

- **Low profit margin (industry characteristics of wholesalers)**
⇒ High-value-added businesses, such as products developed in-house and overseas expansion, including the Kingdom of Thailand
- **Low share in major metropolitan areas (difficult to enter due to high barriers to entry)**
⇒ Nationwide sales through new businesses. About 40% of automated checkout machines are sold in the Kanto region. Sales of OLSTECH and Babyeets also started this year.

- Electronic catalogue
- Integrated logistics system
- Expenditure adjustment system
- Business card management system
- RPA utilization, etc.

● Acquisition of new customers and improvement of revenue

- Develop customers in the Chugoku-Shikoku area
- Proposals for hospital management support, such as purchasing price reductions and insurance claim leakage checks

● Wide-area sales of the Medilia inventory management system

- Voluntary investment type at small and medium hospitals
- Simple and accurate inventory management
- Inexpensive billing and remote maintenance



With customer satisfaction
Improve productivity

YouTube video <https://www.youtube.com/watch?v=iYxAzGT6Utl>

• Increase market share in existing areas

- Strengthen customer service by enhancing follow-up system
- Promote sales activities using ICT

• Strengthen services and sell goods

- Strengthen transactions with nursing care facilities
- Hearing aids sales and wheelchair repair services



• In-house construction of residential remodeling for nursing care

- Cultivating new users
- Providing Safety and Security Services



Nursing bed



Wheelchair



Hearing aids

**Planning to open additional stores
in the Seto Inland Area**



Reference Materials



OLBA
HEALTHCARE

Corporate Profile

Trade name Olbas Healthcare Holding Inc
 (Former name: Kawanishi Holdings Co., Ltd.)

Head Office 1-3, Shimo-Ishii 1-chome, Kita-ku, Okayama

Founded in May 1921

Established October 1967.


Representative Director and President Yohei Maeshima

Capital 607750000 yen

Employees 1367 (Consolidated, as of December 31, 2024)

Fiscal Year Ended June

Mar. 2020 Listed on the First Section of the TSE Stock Exchange
2022 Apr. Transitioned to standard market



Diverse business portfolio encompassing orthopedics, cardiovascular, surgical, ophthalmology, and nursing care

History

May, 1921	Established Kawanishi Kikai Kikai Store in Ounji-cho, Okayama City (currently Chuo-cho, Kita-ku, Okayama City).
Sep. 1927	Associated company Kawanishi Machinery Shop reorganized and established.
Jun 1950	Reorganized and established Kawanishi Kikiten Co., Ltd.
1967 Oct	Reorganized and established Kawanishi Medical Equipment Co., Ltd.
1985 Oct	Established Life Care Co., Ltd.
Jul 1996	Established Hosnet Japan Co., Ltd.
1999 Jan.	Merged with three companies, Kagawa Seiki Co., Ltd. and Shikoku Medical Abilities Co., Ltd. At the same time, the company changed its name to Kawanishi Co., Ltd.
2000 Dec	Listed on the Second Section of the Tokyo Stock Exchange.
2004 Jan.	The business division was established as Kawanisi Co., Ltd. through a new split company. At the same time, the company name was changed to KAWANISHI Holdings Co., Ltd.
Jun 2005	Acquired 100% of the shares of Nikko Medical Instruments Co., Ltd.
2012 Jan.	Acquired 100% of the stock of Sansey Medical Machinery Co., Ltd.
2014 Aug.	Head office moved to 1-1-3, Shimo-Ishii, Kita-ku, Okayama, in line with the expansion of the Group's business scope.
2016 Jan.	Established Exora Medical Co., Ltd.
Jul 2019	Established Kawanishibarkmed Co., Ltd.
2020 Mar	Listed on the Second Section of the Tokyo Stock Exchange to the First Section of the Tokyo Stock Exchange.
2021 Jan.	To commemorate its 100th anniversary, the company changed its name to Orba Healthcare Holdings, Inc.
2022 Apr	Transitioned to a standard market in accordance with a review of market categories on the Tokyo Stock Exchange.
Jun 2022	Acquired 100% of the shares of Kawanishibarkmed Co., Ltd.
2023 Jan.	Established Thailand Healthcare Co., Ltd. (THAI OLBA Healthcare Co., Ltd.) in the Kingdom of Thailand.
2024 Jan.	Orsid Co., Ltd. was established.

OLBA Employee Charter

Business Structure

- Contribute to the development of medicine, medical care, and nursing care through business and contribute to the health and longevity of the national
- Promptly and appropriately provide patients and medical providers with the benefits of innovative new features and technologies
- In good faith and continuously to our stakeholders (customers, business partners, employees, local communities, and shareholders)
 - Providing Value and Pursuing Sustainable Management
- Actively interact inside and outside the industry, foster creativity, and explore frontiers from a global perspective

Organizational Structure

- Respect for human resource development and place emphasis on "management (through human resources)"
- Emphasizing Diversity and Recognizing Diverse Opinions, Values, and Working Styles
- Try to compete and trade fairly at any time
- Results from competition are reinvested to create new value
- Develop an environment where members can be healthy both mentally and physically and have a willingness to contribute

How Members Are

- Have a willingness to grow voluntarily and independently
- Continue to learn modestly without being comfortable with past results
- Not good at free riding to benefit without their own contributions or efforts
- Respect business partners inside and outside the company and engage in business with high ethical standards and pride

Consolidated Balance Chart (2Q, 2025)

Millions of yen

Assets	Amount	Change	Liabilities and Net Assets	Amount	Change
Cash and deposits	2,643	△87	Trade payables	28,416	2,216
Trade receivables	27,824	1,711	Short-term borrowings	2,700	2,100
Commodities	7,165	1,222	Other	1,805	△1,110
Other	625	△175	Total current liabilities	32,921	3,206
Total current assets	38,257	2,671	Lease obligations (solid)	953	61
Tangible fixed assets	5,127	767	Other	1,399	142
Intangible fixed assets	625	△20	Total long-term liabilities	2,352	203
Investments and other assets	2,766	120	Total liabilities	35,273	3,410
Total fixed assets	8,518	867	Total net assets	11,502	128
Total assets	46,776	3,538	Total liabilities and net assets	46,776	3,538

※ Change from previous year-end

Net assets per share 1,941.42 yen

Consolidated Statements of Cash Flows (FY2025 2Q)

	Millions of yen	FY June 2024 2nd quarter	FY June 2025 2nd quarter
Income before income taxes		745	815
Depreciation and amortization		259	289
Decrease (increase) in notes and accounts receivable-trade (increase in Δ)		Δ1,629	Δ1,711
Decrease (increase) in inventories (increase in Δ)		Δ429	Δ1,147
Increase (decrease) in notes and accounts payable-trade (decrease in Δ)		1,474	2,216
Other		Δ565	Δ1,261
Operating cash flow		Δ145	Δ799
Payment for acquisition of tangible fixed assets		Δ154	Δ797
Purchases of intangible assets		Δ87	Δ83
Loans to subsidiaries and affiliates		Δ100	-
Other		Δ33	Δ8
Investing cash flow		Δ374	Δ888

Consolidated Statements of Cash Flows (FY2025 2Q)

		Millions of yen	FYE June 2024 2nd quarter	FYE June 2025 2nd quarter
	Net increase (decrease) in short-term borrowings (Δ)		1,800	2,100
	Repayments of long-term debt		Δ55	-
	Purchase of treasury stock		Δ221	Δ135
	Proceeds from sales of treasury stock		1	139
	Dividends paid		Δ435	Δ488
	Other		Δ76	Δ77
	Financial cash flow		1,014	1,539
	Net increase (decrease) in cash and cash equivalents (decrease in Δ)		521	Δ148
	Cash and Cash Equivalents at Beginning of Year		2,359	2,681
	Other		-	60
	Cash & cash equivalents at year-end		2,881	2,593

Consolidated Financial Data ①

Item	Unit	2020/6	2021/6	2022/6	2023/6	2024/6
Net sales	Millions of yen	97,872	102,072	107,959	110,472	118,564
Operating income	Millions of yen	927	1,540	2,073	2,151	2,226
Ordinary income	Millions of yen	905	1,542	2,119	2,158	2,244
Profit attributable to owners of parent Net income	Millions of yen	326	989	1,535	1,414	1,500
Net assets	Millions of yen	7,281	8,131	9,093	10,327	11,373
Total assets	Millions of yen	33,683	36,562	39,968	40,878	43,237
BPS	Yen	1,197.17	1,336.91	1,513.91	1,712.19	1,922.58
EPS	Yen	56.76	162.66	252.80	234.90	251.68
Equity ratio	%	21.6	22.2	22.8	25.3	26.3
ROE	%	4.7	12.8	17.8	14.6	13.8
ROA	%	2.7	4.4	5.5	5.3	5.3
PER	Times	23.85	10.17	6.63	7.70	8.01
PBR	Times	1.13	1.24	1.11	1.06	1.05

Consolidated Financial Data ②

Item	Unit	2020/6	2021/6	2022/6	2023/6	2024/6
Sales CF	Millions of yen	862	3,126	2,420	△659	2,084
Investment CF	Millions of yen	△496	△630	△211	△306	△673
Finance CF	Millions of yen	439	△2,262	△1,169	175	△1,089
Cash and cash equivalents	Millions of yen	1,877	2,110	3,149	2,359	2,681
Bank loans	Millions of yen	2,615	795	275	955	600
Number of employees	People	1,222	1,261	1,289	1,317	1,354
Medical equipment	People	892	913	938	955	982
Of which, SPD	People	171	177	175	177	174
Nursing care	People	120	131	135	138	147
Imports and sales	People	2	-	-	-	-
Of which, headquarters	People	37	40	41	47	51

※ Import and sales business is excluded from June 2021.

(Previous fiscal year) Consolidated results for the fiscal year ended June 2024

Record highs for net sales, gross profit, operating income, and ordinary income

	Millions of yen	Comparison with budget	YoY change
Net sales	118,564	+0.2%	+7.3%
Gross profit	13,600	Δ2.0%	+5.0%
Gross profit margin	11.47%		
SG&A expenses	11,374	Δ2.6%	+5.3%
Operating income	2,226	+1.2%	+3.5%
Ordinary income	2,244	+1.6%	+4.0%
Profit attributable to owners of parent	1,500	+3.3%	+6.1%

Net income per share ¥251.68

(Previous year) Summary of results for the year ended June 2024

※New highs for net sales

Net sales

118.5 billion yen
(+7.35% YoY)

ROE

13.8%
(5-year average of 12.7%)

Dividend yield

4.0%
(*As of June 30, 2024)

※New highs for net sales

Operating income

2.22 billion yen
(+3.5% YoY)

PBR

1.05 times
(*As of June 30, 2024)

DOE

Dividends on Equity
4.4%
(*As of June 30, 2024)

CSR Initiatives Contributing to Social Rooted in Local Communities

Working together with local residents to create a future conducive to regional development and revitalization

Faziano Okayama Club sponsor

Established in 2006 as Okayama Prefecture's first professional soccer club
Decided to be promoted to J1 in 2024



Okayama TEC PLANTER Partner companies

With the creation of new businesses based on technologies originating in Okayama
Venture development and support



Okayama Rivets Team sponsor

Male Table Team established in 2018
Participated in the national T league



Ohara museum of art Official partner

Established in 1930 in Kurashiki City, Okayama Prefecture
Japan's first private art museum focusing on western art



Nippon Medical Manufacturing Commons MINC Association "Study Group on the Latest Trends in Overseas Medical Devices"

On Medical Globe

Sharing and discussing information on the latest overseas medical device information among various industries

Doctors, manufacturers, the Ministry of Economy, Trade and Industry, the Ministry of Health, Labour and Welfare, the Patent Office, AMED • PMDA

Our MG Editorial Department participates and exchanges views (started in October 2017)

33rd Meeting: National Center for International Medical Research to be held online in March 2025



Corporate Information/Inquiries

[Fiscal year] From July 1 to June 30 of the following year

[Ordinary General Meeting of Shareholders] Held annually in September

[Stock Exchange Lists] Tokyo Stock Exchange (Standard Market)

Securities code: 2689

[Number of shares per unit] 100 shares

[Contact] OLBA HEALTHCARE HOLDINGS, INC.

Nobuyuji Murata Managing Director, Chief Administrative Officer

info@olba.co.jp

- Although the datum provided in this document is intended to be used with all possible care, the accuracy and completeness of such information is not guaranteed.
- Opinions and forecasts contained in the data are our forecasts based on information available at the time of preparation of the materials, and we do not guarantee any compensation for the results of using such opinions and forecasts. The information in this document is subject to change without notice.
- This material is intended to provide a better understanding of us and is not necessarily intended as a recommendation to invest. We asked investors to make their own decisions on the final outcome of their investments.